drugset / Trial / NCT00222677

Aspirin for the Prevention of Recurrent Venous Thromboembolism

NCT00222677

Phase 2/3 Unknown 70 enrolled University Of Perugia
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To determine whether aspirin is more effective than placebo for the prevention of recurrent symptomatic venous thromboembolism when given for at least two years after the initial 6-12 month of oral anticoagulant therapy in patients with idiopathic venous thromboembolism

Timeline

Start
2004-05
Primary completion
2012-01
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Aspirin Small molecule 100 mg